Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics announces interim data from cohort one of RIDGE-1 trial
- Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA
- Tenaya Therapeutics Reports Improved Financials Amid Strategic Focus
- Promising Outlook for Tenaya Therapeutics’ TN-201 Program Despite Procedural Clinical Hold
- Tenaya Therapeutics reports Q3 EPS (12c), consensus (15c)